Literature DB >> 6309678

Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients.

D J Moss, S H Chan, S R Burrows, T S Chew, R G Kane, J A Staples, N Kunaratnam.   

Abstract

There is a substantial body of evidence suggesting an association between Epstein-Barr virus (EBV) and undifferentiated nasopharyngeal carcinoma (NPC). The present study has compared a group of NPC patients (newly diagnosed and long-term survivors) and controls for EBV-specific T-cell immunity using the regression of transformation assay. Newly diagnosed patients (17 tested) when compared with either long-term survivors (20 tested) or controls (30 tested) showed a significant impairment in virus-specific T-cell immunity (p = 0.036, p = 0.043 respectively). Furthermore, donors with IgA antibody to EBV showed a significant depression in virus-specific T-cell immunity compared with donors without IgA antibody (19 IgA-positive, 48 IgA-negative; p = 0.0025). These results may be important in explaining the postulated role of EBV in the aetiology of NPC.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309678     DOI: 10.1002/ijc.2910320307

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

2.  Emergence of non-major-histocompatibility-complex-restricted lytic CD8+ cells in the blood of nasopharyngeal carcinoma patients.

Authors:  M Lakhdar; H Thameur; M Maalej; F Ben Ayed; A Ladgham
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

3.  Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.

Authors:  Nehla Mokni Baizig; Patrice Morand; Jean Marie Seigneurin; Hamouda Boussen; Asma Fourati; Said Gritli; Zeineb Oueslati; Slim Touati; Amor Gamoudi; Mansour Ben Abdallah; Michèle El May; Ahmed El May
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-07-30       Impact factor: 2.503

4.  Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.

Authors:  M Sugiura; S Imai; M Tokunaga; S Koizumi; M Uchizawa; K Okamoto; T Osato
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

5.  Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma.

Authors:  Mark Fogg; John R Murphy; Jochen Lorch; Marshall Posner; Fred Wang
Journal:  Virology       Date:  2013-04-17       Impact factor: 3.616

6.  Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.

Authors:  Mark H Fogg; Lori J Wirth; Marshall Posner; Fred Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-11       Impact factor: 11.205

Review 7.  Immune regulation in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows; D J Moss
Journal:  Microbiol Rev       Date:  1995-09

8.  Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro.

Authors:  Kara Bickham; Kiera Goodman; Casper Paludan; Sarah Nikiforow; Ming Li Tsang; Ralph M Steinman; Christian Münz
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

9.  T-cell receptor gene expression in tumour-infiltrating lymphocytes and peripheral blood lymphocytes of patients with nasopharyngeal carcinoma.

Authors:  Y Chen; C T Chew; S H Chan
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

10.  Lymphocyte subsets in tumour of patients with undifferentiated nasopharyngeal carcinoma: presence of lymphocytes with the phenotype of activated T cells.

Authors:  P Herait; G Ganem; M Lipinski; C Carlu; C Micheau; G Schwaab; G De-The; T Tursz
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.